Study wrapper · #1380
A Biweekly GLP-1R Agonist Designed With Drug-Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability.
Ding W, Liu Q, Luo Q, et al. Diabetes, obesity & metabolism. 2026.
DOI: 10.1111/dom.71304PubMed: 42712076
Animal (in vivo)Mentions: Semaglutide
Editor's note
Entirely preclinical — rodents plus a primate pilot — and the head-to-head framing against semaglutide deserves the usual caution about dose-matching across different dosing schedules. The 'GLP-1R recovery' concept, letting the receptor recycle during drug-free windows while continuous semaglutide exposure drives internalization, is a genuinely interesting design hypothesis with possible tolerability implications. Years from human data, if it gets there at all.
Plain-language abstract
Researchers engineered CT130, a longer-acting semaglutide derivative dosed every two weeks with deliberate drug-free intervals, and report better weight and metabolic results than weekly semaglutide in mice, plus over 10% weight loss in a small monkey pilot.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026